The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo

A phase 2 clinical trial investigating the efficacy and safety of AS602801, a newly developed JNK inhibitor, in the treatment of inflammatory endometriosis is complete. We are now examining whether AS602801 acts against human cancer cells in vitro and in vivo. In vitro, AS602801 exhibited cytotoxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Masashi, Kuramoto, Kenta, Takeda, Hiroyuki, Watarai, Hikaru, Sakaki, Hirotsugu, Seino, Shizuka, Seino, Manabu, Suzuki, Shuhei, Kitanaka, Chifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053629/
https://www.ncbi.nlm.nih.gov/pubmed/27027242
http://dx.doi.org/10.18632/oncotarget.8395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053629/
https://www.ncbi.nlm.nih.gov/pubmed/27027242
http://dx.doi.org/10.18632/oncotarget.8395

Ejemplares similares